SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

Summary

This study is a randomized, open-label, controlled, multicenter phase II clinical trial, which aims to evaluate the safety and efficacy of SYS6002 versus enfortumab vedotin in the treatment of participants with advanced urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will be initiated only after formal approval is obtained from the relevant Ethics Committee or Institutional Review Board.

Timeline

Start

2026-06-20

Primary completion

2028-06-01

Completion

2028-12-01

Drugs

Indications